Sun Yat-sen University Cancer Center (SYSUCC) was established in 1964 and is one of the four earliest tumor hospitals in China. SYSUCC is leading the way on a national frontier. It is the largest integrated cancer center in the whole of southern China for cancer care, education, research and prevention.
SYSUCC is a modern medical service provider equipped with 1489 ward beds, 32 clinical departments, 8 administrative offices and 2 research departments. In 2016, the center performed 830,000 out-patients consultations and 94,000 patients were hospitalized, providing the largest volume of cancer medical service in China. Equipped with state of the art medical technology, SYSUCC has a premier radiation therapy center and recently introduced the da Vinci robot for minimally invasive surgeries.
Sun Yat-sen University Cancer Center has been awarded many prestigious titles: the National Key Disciplines (Oncology), the State Key Laboratory (SKL) of Oncology in South China, etc. SYSUCC has always closely combined its clinical and research attributes, ranking top two in the Chinese Hospital of Scientific Impact Ranking.
Altogether, seventy-five projects have been awarded with scientific achievement awards of provincial level or above, including one project with the second prize of “National Natural Science Award”, four projects with the second prize of “National Science and Technology Progress Award”. SYSUCC houses the editorial office of the Chinese Journal of Cancer (CJC). In 2014, CJC became Science Citation Indexed (SCI), and its impact factor of 2015 reached 2.814, ranking first among the national journals of Oncology.
With over 2,500 staff members, Sun Yat-sen University Cancer Center has recruited a talented team for patient care, education and scientific research. Through infrastructure optimization, software and management system upgrades, SYSUCC has created an efficient working environment for its employees, as well as a patient-oriented atmosphere. In 2016, SYSUCC was ranked first in the Chinese Hospitals Best Employer Ranking.
With the establishment of high level research platforms, a mature discipline structure as well as strong funding support, SYSUCC is now offering generous post-doctoral researcher benefits and promising career opportunities. In 2017, 79 post-doctoral positions will be made available at SYSUCC. Enthusiastic applicants with a recent PhD and related research background are strongly encouraged to apply. Join us and investigate in the fields of cancer treatment and prevention.
Eligibility Requirements:
1. Good general health, with a doctor’s degree, high academic achievements and strong research ability
2. For recent PhD graduates: you must be under the age of 35 and have completed your PhD degree within the last 2 years.
For Post-docs from industry, postdoctoral bases, abroad, foreign or outstanding applicants: must be under the age of 40.
3. To commit to a full-time employment position.
4. For SYSU PhD graduates only: you must not apply to the Postdoctoral Training Station for the same discipline.
Welfare and Benefits
1. Annual salary: 200,000 – 250,000 RMB (before tax)
2. Pay the basic social insurance and housing fund (for Chinese applicants)
3. Guangzhou hukou (for Chinese applicants)
4. Post-docs with excellent academic performance can apply for a researcher’s position in SYSUCC afterwards
Requirement for Postdoctoral Training Completion
You must publish at least one SCI paper with an impact factor above 3.0 and receive at least one research funding grant in order to gain the post-doc training certificate. Information and help about funding opportunities at that stage will be disclosed at a later date.
Total number of enrollment: 77
Application procedure
1. Please communicate first with potential supervisors. Attached is the contact information and research specialty for each of the supervisors. You can also check SYSUCC official website or the following website: http://rsc.sysu.edu.cn/postdoctor/
2. Please submit your CV by: (1) sending it to your supervisor via email. (2) submit it online to our Chinese website (3) send it to our Human Resources Department, and we will then help to recommend you to suitable supervisors
3. Interview: experts from the Post-doc Administration Group are in charge of interviewing all applicants (international applicants can be interviewed via teleconferencing). A 15-30 minute academic presentation is required, including a general self-introduction, introduction of your former research experience as well as your future work plan.
4. Document submission: applicants should prepare all the materials as required (http://rsc.sysu.edu.cn/PostDoctor/Article/ShowArticle.asp?ArticleID=1088), and submit them to the following website: http://www.chinapostdoctor.org.cn/WebSite/program/Default.aspx Please prepare the related documents for review by our HR team.
5. Approval: After approval by our HR, documents will be submitted to the Office of Post-doctor Management at Sun Yat-sen University, and then to the Personnel Department of Guangdong Province for final approval. The whole procedure takes approximately 30 days.
Contact
Contact person: Mrs. Yang, Mrs. Wen
Address: Personnel Department, Sun Yat-sen University Cancer Center, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou, China
Tel: +86 20 87343130, +86 20 87343129
Email: yangping@sysucc.org.cn
QQ: 157357002
Recruitment Information
|
| Supervisor(s) | Second level discipline | Field of Research | Enrollment |
| 1 | Xiaojun Xia | Molecular Medicine | Innate immunity & Cancer immunotherapy | 2 |
| 2 | Xuekui Liu | Head and neck /oncology otolaryngology | Basic and clinical research of laryngeal cancer | 1 |
| 3 | Yi-Xin Zeng | Oncology | Mechanisms of cancer pathogenesis and biotherapy | 2 |
| 4 | Bi-Jun Huang | Oncology | Cancer stem cells | 1 |
| 5 | Dongxin Lin | Oncology | Molecular Oncology | 2 |
| 6 | Jian Zheng | Oncology | Molecular Oncology | 1 |
| 7 | Shijun Wen | Oncology, Medicinal Chemistry | Anticancer drug discovery and the development of organic synthetic methodology | 2 |
| 8 | Shuai Chen | Oncology | Immune regulation and carcinogenesis | 2 |
| 9 | Hailin Tang | Oncology | Oncology or Molecular Medicine | 1 |
| 10 | Jun Ma | Radiotherapy of Oncology | Molecular prognosis and multidisciplinary precision therapy of nasopharyngeal carcinoma | 4 |
| 11 | Shi Ming | Oncology | hepatocellular carcinoma | 1 |
| 12 | Jianyong Shao | Oncology | Tumor high-throughput sequencing and data mining | 1 |
| 13 | Xiaoxing Li | Oncology | Molecular Oncology | 1 |
| 14 | Xiao-Feng Steven Zheng | Oncology | Molecular Oncology | 3 |
| 15 | Yue Lu | Oncology | Hematologic Oncology | 1 |
| 16 | Zhong-ping Chen | Oncology | Vascular mimicry | 2 |
| 17 | Jiang Li | Oncology | Cancer Immunology | 1 |
| 18 | Yunfei Xia | Oncology | Radiation Oncology | 1 |
| 19 | Liwu Fu | Oncology | Cancer Pharmacology | 3 |
| 20 | Xin-Yuan Guan | Molecular Biology | Microenvironment and tumorigenesis | 1 |
| 21 | Yan Li | Oncology | Molecular tumorigenesis | 1 |
| 22 | Quentin Qiang Liu | Oncology | Molecular Target Therapy | 2 |
| 23 | Rui-hua Xu | Oncology | Precise treatment in gastrointestinal cancer | 5 |
| 24 | Musheng Zeng | tumor biology／virology | EBV infection and EBV vaccine/tumor marker and molecular imaging/ Tumor immune mechanism and immunotherapy | 2 |
| 25 | Song Gao | Molecular Medicine | Structural study of anti-tumor drug targets | 1 |
| 26 | Ying Sun | Radiation oncology | Molecular prognosis and multidisciplinary precision therapy of nasopharyngeal carcinoma | 2 |
| 27 | Jing Tan | Oncology | Precision Medicine of Cancer | 4 |
| 28 | Ran-yi Liu | Oncology or Molecular Medicine | Malignant tumor targeting therapy | 2 |
| 29 | Peng Huang | Oncology, molecular medicine, pharmacology | Regulatory mechanisms of metabolic alterations in cancer and pharmacological intervention. Development of novel anticancer agents. | 3 |
| 30 | Anhua Li | Medical Ultrasound | Interventional Ultrasound | 1 |
| 31 | Chao-Nan Qian | Oncology | The molecular mechanisms underlying metastasis or vessel co-option in solid tumor | 1 |
| 32 | Wenlin Huang | Oncology or Molecular Medicine | Cancer Molecular Biology | 2 |
| 33 | Limin Zheng | Oncology | Tumor immunology | 1 |
| 34 | Xiao-Feng Zhu | Oncology | Signal transduction and targeted anticancer drug | 1 |
| 35 | Zhang Li | Medical Oncology | 1、Studies of preclinical drug treating lung cancer and nasopharyngeal carcinoma； 2、Molecular classification and targeted drug therapy of lung cancer and nasopharyngeal cancer | 2 |
| 36 | Bei Jin-Xin | Oncology | Cancer Genetics and Genomics；Bioinformatics | 2 |
| 37 | Dan Xie | Oncology | The mechanisms of metastasis in GI tumors | 2 |
| 38 | Wei-Hua Jia | Oncology/Epidemiology | Cancer genetics and genomes; Cancer epidemiology | 2 |
| 39 | Fangjian Zhou | Oncology | The mechanism of bladder urothelial carcinoma | 1 |
| 40 | Xing Zhang | Oncology | New molecular targeted therapy and immunotherapy | 1 |
| 41 | Fujun Zhang | Oncology | Molecular imaging；Minimally invasive treatment of tumor | 2 |
| 42 | Wuguo Deng | Oncology | Tumor gene expression regulation | 2 |
| 43 | Jianchuan Xia | immunotherapy | Tumor immunotherapy, Tumor etiology | 1 |
| 44 | Hai-Qiang Mai | Clinical medicine | Nasopharyngeal carcinoma | 1 |
| 45 | Shi-Juan Mai | Oncology | Tumor metastasis biomarker | 1 |
| 46 | Li-Bing Song | Oncology; Molecular medicine | Molecular Mechanism & Biomarker of Tumor | 1 |
Copyright：Sun Yat-sen University Cancer Center Designed by Wanhu.